{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"42"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"SD"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"PD"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"NE"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"description":"The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.","groups":[{"description":"ACP-196 (acalabrutinib) 100 mg BID","id":"OG000","title":"ACP-196 (Acalabrutinib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population included all treated subjects.","reportingStatus":"POSTED","timeFrame":"From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days","title":"Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.","type":"PRIMARY","unitOfMeasure":"Participants"}